COVID-19 Pneumonia
Conditions
Keywords
COVID-19, Critical Case, DNA Repair, DAN damage
Brief summary
Our aim in this study is to determine the positive effect of stem cell therapy applied on critically ill patients with coronavirus infection on DNA repair genes. Patients diagnosed with COVID-19 infection are divided into two equal (n:30) groups. Group-1(n/15): Patients in critically ill condition receiving conventional therapy, Group-2 (n/15): Patients in critically ill condition receiving conventional therapy and systemically transplanted MSCs. The DNA repair pathway will be examined as 11 genes in 5 different parts. Investigated parameters: 1. Base excision repair 2. Nucleotide excision repair 3. Recombinational repair 4. Mismatch repair 5. Direct reversal Investigated parameters: broad biochemical analysis, apoptosis, clinical outcome, and mortality rates.
Detailed description
Our aim in this study is to determine the positive effect of stem cell therapy applied on critically ill patients with coronavirus infection on DNA repair genes. Patients diagnosed with COVID-19 infection are divided into two equal (n:30) groups. Group-1(n/15): Patients in critically ill condition receiving conventional therapy, Group-2 (n/15): Patients in critically ill condition receiving conventional therapy and systemically transplanted MSCs. The DNA repair pathway will be examined as 11 genes in 5 different parts. Investigated parameters: 1. Base excision repair 2. Nucleotide excision repair 3. Recombinational repair 4. Mismatch repair 5. Direct reversal Investigated parameters: broad biochemical analysis, apoptosis, clinical outcome, and mortality rates.
Interventions
BIOLOGICALMesenchymal Stem Cells Transplantation
Mesenchymal Stem Cells Transplantation applied as three intravenous infusions with 30 days intervals
Sponsors
Istinye University
Liv Hospital (Ulus)
SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. 40-65 years old male/female. 2. Obtaining informed consent from him or his legal relative. 3. Confirmed COVID-19 related severe ARDS cases.
Exclusion criteria
pregnant, malignant tumours, the ones who has confirmed co-infection; history of using long-term immunosuppressive agents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Expression of PARP1 gene as indicator of base excision repair | 6 months | Expression of PARP1 gene as indicator of base excision repair |
| Expression of genes ATM, RAD51, RAD52 and WRN as indicator of Recombinational repair | 6 months | Expression of genes ATM, RAD51, RAD52 and WRN as indicator of Recombinational repair |
| Expression of genes RAD23B and ERCC1 as indicator of Nucleotide excision repair | 6 months | Expression of genes RAD23B and ERCC1as indicator of Nucleotide excision repair |
| Expression of genes MLH1, MSH2 and MSH6as indicator of Mismatch repair | 6 months | Expression of genes MLH1, MSH2 and MSH6 as indicator of Mismatch repair |
Countries
Turkey (Türkiye)
Outcome results
None listed